Mohamed Sadeq Ali Presents AccurKardia at LSI Europe '23

Transcription

Sadeq Ali  0:05  
First off, thank you for for having us. My name is Sadeq Ali I am actually now the Chief Operating Officer of AccurKardia. I'm also a co founder of the company it's good to be back here I think really every conference that I've been to you seem to be out doing its God so thanks for having us and and we are happy to join you here so we all know that ECGs are critical to cardiologists as Arsenal they're at least as critical as a stethoscope is to a general practitioner or an ultrasound is to gynecologist, and this has been the case for for more than a century really. But today, what we're finding is that as we begin to better understand comorbidities, we're starting to see the overlap between cardiovascular disease and other metabolic diseases in particular, diabetes and chronic kidney disease. Globally, about 476 million people, which is about 6% of the world population suffer from diabetes of these very large numbers suffer from type two diabetes. In the US alone about 32 point 6 million people are one in 10 of the US population suffer from type two diabetes. Diabetes is one of the most common causes of CKD. Approximately 30 to 40% of patients with diabetes develops CKD. Nearly one half of all patients with CKD, particularly stage four and stage five CKD develop cardiovascular disease and approximately 40 to 50% of all deaths in this population are associated to cardiovascular mortality due to things ranging from heart failure through to fatal arrhythmias. In the US alone, 12 million people are at risk of this, as most of the world ages and as chronic disease becomes a bigger and bigger problem, management becomes ever more critical. In this context, the value of an ECG and particular the change in an ECG for an individual becomes paramount. We believe that ECG is today are at the cusp of becoming one of the most if not the most critical biomarker in diagnostics and disease management. There are three reasons why we hold this belief. The first we discussed extensively in the previous slide the interplay between metabolic diseases and cardiovascular disease. The second is because one of the most interesting aspects of an ECG is that the ECG is very unique to an individual to an extent that some consider ECG as a potential biometric. In this context, an individual's ECG and the change in a person's ECG becomes very critical. I witnessed this firsthand myself and suffering through the the Delta variant of COVID, a couple of years ago, very carefully tracked my ECG through through that time, I was able to see how it changed from the point where I was getting sick to the point where I was sick. And to the point where I became healthy again, this is this is anecdotal, but beyond that, we definitely see, you know, a lot of studies that have basically said the same thing. Another point to keep in mind is that in some ways, ECG offers a benefit compared to the other broad diagnostics out there. In particular blood and DNA. ECG has some significant advantages, both from a remote monitoring perspective, as well as a continuous monitoring perspective, it's non invasiveness in nature, much more cost effective than blood and DNA. The ease of acquisition, particularly on a single lead ECG is far greater than what you'd find on anyone trying to do a blood draw or obviously gene sequencing of any sort. Today, three key elements are are basically coming together to make ECG as a biomarker on a planetary scale viable. The first the proliferation of ECG sensors and like literally everything from watches through the steering wheels of automobiles, all the way through the toilet seat. I think about three months ago, the FDA approved a toilet seat with an ECG sensor embedded in it. The other part of it is artificial intelligence, both in the cloud and the edge. And then the third aspect of it is telehealth, which is critical particularly to last mile care and a situation in which intervention might be required. However, the current ECG interpretation approaches leave a lot to be desired. In studies performed by various publications, including the Journal of the American Medical Association internal medicine, the median accuracy of ECG interpretation by trained physicians is around 54%. This is not a one off study, study after study has shown this. From a speed perspective, it's even worse in some cases, it can take anywhere from two days to two weeks for a prescribing physician to get the results of a 24 hour hold recording. Current solutions are just not adequate to handle accuracy, speed and scale at a regional scale, leaving on at a planetary one. So we attack your cardio are are going to change that, indeed doing so we'll unlock the value of ECG truly at a planetary scale. And why do we believe we can do this because in many ways we've achieved this in the context of our very first product, there are certain things that are required certain key features to make this possible. First off, in order to do this well, you need to be you need to have a device that's that's, that's agnostic to the hardware. Our very first product accuracy G received FDA clearance a couple of months ago. And that particular product works with with lead to have wet electrode devices, which includes everything from holsters to vent monitors to mobile cardiac telemetry devices, also known as MCT is the second product in our pipe pipeline accurate beat, which isn't yet FDA cleared, works with dry leads, and in particular, the Apple Watch, and is able to do so without any underlying changes to our analytics engine. Beyond that, you need clinical grade accuracy. So we've achieved what we've spoken about from a device agnostic perspective, without, without a con without suffering anything on the accuracy site standpoint, we'll talk a little bit more about what those accuracy numbers are in the next slide. The software needs to be near real time. In our case, the software works relatively real time within the first 30 seconds, we are able to interpret the data, and for every subsequent millisecond, we do it in real time. We have very broad diagnostic coverage already in the arrhythmia use case and we are developing products beyond arrhythmia at this point. And from an from a workflow perspective, we've enabled it through an API, which enables other hardware and software providers to basically leverage our solution within the context of their solutions. So accurately CG, this was the product that has been approved by the FDA for the detection of up to 13 arrhythmias, including critical atrial arrhythmias such as atrial fibrillation and atrial flutter, first degree AV blocks as well as critical ventricular arrhythmias. In particular when ticular attack Acharya Accu cardia takes are accurate ECG I should say it takes what used to be a two day to two week process and reduces it to two hours if not minutes of a software product does beat by beast analysis and reduces the time spent by a cardiac technician by up to about 70%. This allows our target customers alters event monitors MCT manufacturers to reduce their overhead costs significantly. The commercial opportunity presented by QB CG is very large the times well in excess of $4 billion in the US alone. Our immediate product pipeline is strong, and it covers products both in the traditional heart rhythm space and in the detection of diseases not traditionally diagnosed by ECG, including hyperkalemia cardiac amyloidosis, and aortic valve stenosis or ABS, or hyperkalemia model was built based on lead one ECG data and developed and validated at the Mayo Clinic validation was performed with retrospective data of 3500 unique patient records and perform perform very well. We received sensitivities of 81%, specificity of 83% and an AUC of about 89%. Our results for cardiac Amyloidosis and abs are similarly attractive of a target partners for some of the new IP ranges from dialysis companies for the hyperkalemia use case through the pharma companies for both the hyperkalemia and the cardiac Amyloidosis use case. And, and for as far as ABS is concerned, our manufacturers would be who would who we target. The terms for each of these are also very, very attractive and increasing year on year, we have raised approximately $4.3 million up to this point, which includes getting our first clearance and are now looking to raise a $15 million series A for commercialization and the further development of our product pipeline. We are global team of AI scientists, researchers, engineers, clinicians and healthcare professionals led by a co leadership team and supported by some of the best advisors in both the clinical and commercial side of healthcare. Accu cardio was formed in 2019. But the r&d efforts predate the formation of the company we started our r&d efforts in early 2015. This year in particular has been a very active one for us. We started off in March 2020 of this year, joining the Mayo Clinic platform accelerate. We completed a seed round closing in June received FDA clearance actually the same week as our seat closing. And, and we recently announced it's called a finalist in the digital health awards. So it's been a great You're for us. And we're looking forward to what's to come next year. Thank you to everyone and if anyone has any questions wants to chat further I'm available for anyone who wants to help us with our Series A I'm available as well to talk outside. And last but not the least thank you to Scott for arranging this event is great. Thank you.